GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences

UK's Cytospire draws in $83m for new T-cell engager platform

Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-663 for Treatment of Multiple Hematologic and Solid Malignancies

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013